Exelgyn

Last updated
Exelgyn
Industry Pharmaceutical
Headquarters Paris, France
Area served
Worldwide
Products mifepristone, misoprostol.
Website https://exelgyn.com/

Exelgyn is a French pharmaceutical company which makes and distributes the medical abortion drugs mifepristone (marketed as Mifegyne) and misoprostol.

Contents

History

Mifepristone was originally developed by the French pharmaceutical company Roussel-Uclaf.

In 1997, after buying the remaining 43.5% of Roussel-Uclaf stock in early 1997, [1] Hoechst AG announced the end of its manufacture and sale of Mifegyne

1997, Exelgyn S.A. was founded, a single-product company immune to antiabortion boycotts, whose CEO was former Roussel-Uclaf CEO Édouard Sakiz. Hoeschst AG transferred all rights for medical uses of mifepristone (outside of the United States) to Exelgyn. [2]

In 1999, Exelgyn won approval of Mifegyne in 11 additional countries. [3] As of 2024, Exelgyn distributes mifepristone to 40 countries, [4] but within the United States it is distributed by Danco Laboratories and GenBioPro.

References

  1. ↑ Moore SD, Kamm T, Fleming C (11 December 1996). "Hoechst to seek rest of Roussel-Uclaf; expected $3.04 billion offer would add to the wave of drug-sector linkups". The Wall Street Journal. p. A3.
    Marshall M (11 December 1996). "Hoechst offers to pay $3.6 billion for rest of Roussel". The Wall Street Journal. p. A8.
    "Hoechst to buy rest of Roussel" . The New York Times . Bloomberg News. 11 December 1996. p. D4. Archived from the original on 25 June 2016.
  2. ↑ "Pill for abortion ends production" . The New York Times . Bloomberg News. 9 April 1997. p. D2. Archived from the original on 25 June 2016.
    Jouzaitis C (9 April 1997). "Abortion pill maker bows to boycott heat; German firm gives up RU-486 patent; little impact likely in U.S." Chicago Tribune. p. 4. Archived from the original on 18 February 2013.
    Lavin D (9 April 1997). "Hoechst will stop making abortion pill". The Wall Street Journal. p. A3.
    "Roussel-Uclaf to transfer RU 486 rights". Reprod Freedom News. 6 (7): 8. 18 April 1997. PMID   12292550.
    Dorozynski A (19 April 1997). "Boycott threat forces French company to abandon RU486". BMJ. 314 (7088): 1150. doi:10.1136/bmj.314.7088.1145m. PMC   2126515 . PMID   9146386.
  3. ↑ "List of mifepristone approval" (PDF). New York: Gynuity Health Projects. 4 November 2009. Archived from the original (PDF) on 26 July 2011. Retrieved 4 May 2018.
    "Map of mifepristone approval" (PDF). New York: Gynuity Health Projects. 4 November 2009. Archived from the original (PDF) on 26 July 2011. Retrieved 11 June 2010.
  4. ↑ https://exelgyn.com/our-global-presence/
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.